The Effectiveness of High-intensity Laser Therapy on Post-surgical Rehabilitation After Total Knee Arthroplasty
The Effectiveness of High-intensity Laser Therapy on Post-surgical Rehabilitation: a Randomized Controlled Trial
This randomized controlled trial aims to evaluate the effectiveness of high-intensity laser therapy (HILT) as an adjunct to conventional rehabilitation in patients undergoing total knee arthroplasty (TKA).
Persistent pain and functional limitations are common after TKA despite standard rehabilitation, highlighting the need for adjunctive therapies to optimize postoperative recovery. High-intensity laser therapy has been proposed as a non-invasive intervention with potential analgesic and anti-inflammatory effects; however, its effectiveness in this population remains unclear.
Participants will be randomly allocated to one of two groups: an experimental group receiving HILT in addition to conventional physiotherapy and a control group receiving sham laser therapy combined with the same rehabilitation program. Both groups will undergo standardized rehabilitation sessions lasting 60 minutes, including 15 minutes of active or sham laser therapy and 45 minutes of conventional physiotherapy.
The primary outcome is postoperative pain. Secondary outcomes include joint swelling, range of motion, muscle strength, physical function, and quality of life.
Assessments will be conducted at baseline (preoperative), at 1 month after surgery (prior to the start of rehabilitation), during the rehabilitation program (after the fourth, seventh, and tenth physiotherapy sessions), and at 4 months postoperatively (follow-up).
A total of 46 participants (23 per group) will be enrolled in the study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lisa Berti, MD
- Numéro de téléphone: 0516366197
- E-mail: lisa.berti@ior.it
Lieux d'étude
-
-
-
Bologna, Italie, 40136
- IRCCS Istituto Ortopedico Rizzoli
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Patients undergoing primary unilateral total knee arthroplasty for primary knee osteoarthritis
- Age between 50 and 80 years
- Pain intensity greater than 30/100 on the Visual Analog Scale (VAS)
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Psychiatric disorders
- Cognitive impairments
- Previous major trauma or surgery involving the affected knee
- Rheumatic diseases or fibromyalgia
- Vascular diseases
- Neoplastic diseases
- Infectious diseases
- Neurological disorders
- Hemophilia or bleeding disorders
- Current anticoagulant therapy
- Presence of a pacemaker
- History of epileptic seizures
- Known hypersensitivity or contraindication to laser therapy
- Suspected conditions in which tissue heating is contraindicated
- Use of photosensitizing medications or known photosensitivity
- Skin lesions or abrasions at the treatment site
- Tattoos in the treatment area
- Intra-articular steroid injections in the target knee within the previous 2-3 weeks
- Recent significant trauma or injury
- Use of anti-inflammatory or analgesic medications or other pain-relieving treatments (if not controlled or standardized)
- Pregnancy or breastfeeding
- Positive status for human immunodeficiency virus
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: High level laser therapy group
High-intensity laser therapy (HILT) will be delivered using the HIRO TT device (ASA S.r.l.), which employs a patented pulsed laser system (FDA-approved in 2003) based on a solid-state Nd:YAG source emitting near-infrared (NIR) radiation at a wavelength of 1064 nm. The device operates with a mean power of 10.5 W and a peak power of 3 kW. Three treatment areas (each measuring 15 × 10 cm) will be targeted: two longitudinal areas over the quadriceps muscle and one transverse area over the knee joint. The treatment will be delivered at a frequency of 15 Hz, with a total energy dose of 2000 J, corresponding to an energy density of 4.5 J/cm². The total treatment time will be 14 minutes and 30 seconds. |
High-intensity laser therapy (HILT) will be delivered using the HIRO TT device (ASA S.r.l.), which employs a patented pulsed laser system (FDA-approved in 2003) based on a solid-state Nd:YAG source emitting near-infrared (NIR) radiation at a wavelength of 1064 nm. The device operates with a mean power of 10.5 W and a peak power of 3 kW. Three treatment areas (each measuring 15 × 10 cm) will be targeted: two longitudinal areas over the quadriceps muscle and one transverse area over the knee joint. The treatment will be delivered at a frequency of 15 Hz, with a total energy dose of 2000 J, corresponding to an energy density of 4.5 J/cm². The total treatment time will be 14 minutes and 30 seconds. |
|
Comparateur factice: Sham laser therapy group
The sham laser intervention will be delivered using the same HIRO TT device and identical treatment procedures as the active HILT group. The same anatomical areas (two longitudinal areas over the quadriceps muscle and one transverse area over the knee joint) will be targeted, with identical session duration and positioning. During sham treatment, the device will remain switched on; however, no therapeutic laser emission will be delivered. This approach is intended to ensure participant blinding by replicating the visual and procedural aspects of the active intervention without providing any active therapeutic effect. |
The sham laser intervention will be delivered using the same HIRO TT device and identical treatment procedures as the active HILT group. The same anatomical areas (two longitudinal areas over the quadriceps muscle and one transverse area over the knee joint) will be targeted, with identical session duration and positioning. During sham treatment, the device will remain switched on; however, no therapeutic laser emission will be delivered. This approach is intended to ensure participant blinding by replicating the visual and procedural aspects of the active intervention without providing any active therapeutic effect. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Visual Analogue Scale
Délai: after 3 weeks
|
The VAS consists of a 100-mm horizontal line anchored by two descriptors: "no pain" (0 mm) and "worst imaginable pain" (100 mm).
Participants will be asked to mark a point on the line corresponding to their perceived level of pain.
The score will be determined by measuring the distance in millimeters from the left end of the line to the patient's mark, with higher scores indicating greater pain intensity.
|
after 3 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Visual Analogue Scale
Délai: Baseline, after 1 week, after 2 weeks, after 4 months follow-up
|
The VAS consists of a 100-mm horizontal line anchored by two descriptors: "no pain" (0 mm) and "worst imaginable pain" (100 mm).
Participants will be asked to mark a point on the line corresponding to their perceived level of pain.
The score will be determined by measuring the distance in millimeters from the left end of the line to the patient's mark, with higher scores indicating greater pain intensity.
|
Baseline, after 1 week, after 2 weeks, after 4 months follow-up
|
|
Range of Motion
Délai: Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up
|
Knee range of motion (ROM) will be assessed bilaterally, both actively and passively, including maximum flexion and full extension. Measurements will be obtained using a digital goniometer. The axis of rotation will be aligned with the lateral femoral condyle. The stationary arm will be aligned with the longitudinal axis of the femur, using the greater trochanter as a proximal reference point, while the movable arm will be aligned with the longitudinal axis of the fibula, using the fibular head and lateral malleolus as reference points. ROM values will be recorded in degrees, with higher flexion values and lower extension deficits indicating better joint mobility. |
Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up
|
|
Swelling
Délai: Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up
|
Knee swelling will be assessed using circumferential measurements (cm) obtained with a flexible measuring tape. Measurements will be performed with the participant in the supine position and the lower limbs in full extension. Circumference will be recorded at standardized anatomical landmarks: 1 cm below the inferior pole of the patella (knee joint line), 10 cm and 20 cm above the patellar base, and 5 cm below the patellar apex. Two measurements will be taken at each site, and the mean value will be used for analysis. Higher circumference values will indicate greater swelling. |
Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up
|
|
Lower limb muscle strength
Délai: Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up
|
Lower limb muscle strength will be assessed using a handheld dynamometer during isometric knee extension and flexion of the operated limb. Participants will perform three maximal voluntary isometric contractions for each movement, each lasting 5 seconds, with a 30-second rest interval between repetitions. The mean value of the three trials will be used for analysis. For knee extension assessment, participants will be seated with the hip and knee flexed at 90°. For knee flexion assessment, participants will be positioned prone with the knee flexed at 90°. In both conditions, limb positioning will be standardized using a digital goniometer and stabilized with a fixation strap. The dynamometer will be placed at the distal third of the leg, approximately 10 cm proximal to the ankle joint. The device will be manually stabilized by the assessor to ensure consistent positioning and minimize compensatory movements. Higher values will indicate greater muscle strength. |
Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up
|
|
Western Ontario and McMaster Universities Osteoarthritis Index
Délai: Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up
|
The WOMAC is a patient-reported outcome measure specifically designed for individuals with knee osteoarthritis. It consists of three subscales assessing pain, stiffness, and physical function. The physical function subscale includes items related to activities of daily living such as walking, stair use, sitting, and standing. Each item is scored on a Likert scale, and total scores are calculated by summing item responses. Higher scores indicate worse pain, stiffness, and functional limitation. |
Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LASER_KNEE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .